Deutsche Bank AG Has $99.27 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Deutsche Bank AG raised its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 5.6% during the 4th quarter, HoldingsChannel reports. The firm owned 1,212,706 shares of the company’s stock after purchasing an additional 64,522 shares during the quarter. Deutsche Bank AG’s holdings in Vaxcyte were worth $99,272,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its position in shares of Vaxcyte by 21.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,684 shares of the company’s stock worth $220,000 after purchasing an additional 475 shares during the last quarter. Avior Wealth Management LLC lifted its holdings in shares of Vaxcyte by 21.1% during the fourth quarter. Avior Wealth Management LLC now owns 6,456 shares of the company’s stock worth $528,000 after buying an additional 1,124 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Vaxcyte by 125.1% during the fourth quarter. Blue Trust Inc. now owns 835 shares of the company’s stock worth $68,000 after buying an additional 464 shares during the last quarter. KBC Group NV boosted its position in shares of Vaxcyte by 78.0% in the fourth quarter. KBC Group NV now owns 4,775 shares of the company’s stock valued at $391,000 after acquiring an additional 2,092 shares during the period. Finally, Chicago Partners Investment Group LLC grew its stake in shares of Vaxcyte by 9.2% in the fourth quarter. Chicago Partners Investment Group LLC now owns 5,431 shares of the company’s stock worth $440,000 after acquiring an additional 458 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. The Goldman Sachs Group cut their target price on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Vaxcyte in a research report on Tuesday, April 8th. Guggenheim reissued a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Evercore ISI upgraded Vaxcyte to a “strong-buy” rating in a research note on Monday, March 31st. Finally, Bank of America cut their price target on Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Vaxcyte presently has an average rating of “Buy” and a consensus target price of $136.50.

Vaxcyte Stock Down 0.9%

Shares of PCVX opened at $31.16 on Monday. The company has a 50-day moving average price of $46.66 and a two-hundred day moving average price of $74.19. The stock has a market cap of $4.02 billion, a price-to-earnings ratio of -6.77 and a beta of 1.27. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period last year, the company posted ($0.85) earnings per share. Equities research analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Insiders Place Their Bets

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the sale, the chief operating officer now directly owns 154,931 shares of the company’s stock, valued at approximately $11,351,794.37. This represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.